CRINETICS PHARMACEUTICALS INC. - COMMON STOCK
42.23
10-1月-25 12:36:31
15 分の遅延
株式
-6.27
-12.93%
本日の幅
41.80 - 47.56
ISIN
N/A
ソース
NASDAQ
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 5 2023 15:21:55 提供 Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
04 5 2023 15:05:12 提供 Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 4 2023 15:31:01 提供 Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 3 2023 15:37:50 提供 Nasdaq GlobeNewswire
-
28 2 2023 15:05:39 提供 Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 2 2023 16:21:42 提供 Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
10 2 2023 07:01:33 提供 Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 1 2023 15:48:48 提供 Nasdaq GlobeNewswire
-
09 1 2023 07:01:39 提供 Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 12 2022 15:01:00 提供 Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
28 11 2022 07:00:01 提供 Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
22 11 2022 07:00:02 提供 Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
14 11 2022 07:00:02 提供 Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 11 2022 15:30:43 提供 Nasdaq GlobeNewswire
-
13 10 2022 07:00:02 提供 Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 10 2022 15:57:25 提供 Nasdaq GlobeNewswire
-
Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism
06 10 2022 07:00:02 提供 Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
03 10 2022 07:00:01 提供 Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 9 2022 07:00:01 提供 Nasdaq GlobeNewswire
-
08 9 2022 07:00:01 提供 Nasdaq GlobeNewswire